<DOC>
	<DOCNO>NCT01378650</DOCNO>
	<brief_summary>1 . Overview tinnitus Tinnitus noisy sound perceive without external sound source . According survey US , 10-20 % adult symptom tinnitus 3-5 % tinnitus patient severe discomfort daily life . Severe tinnitus result psychiatric problem depression anxiety disorder . Enhancement environmental sound , hear aid , sound generator , cognitive therapy , transcranial magnetic therapy , drug therapy try treatment tinnitus . Nitric oxide ( NO ) well-known neurotransmitter act vasodilator regulation production cyclic guanosine monophosphate ( cGMP ) find various site cochlea . It report cGMP enhances activity protein kinase A ( PKA ) , mediator platelet aggregation inhibition vasodilatation result increase vascular flow . 2 . Characteristics clinical research drug , cilostazol Cilostazol inhibit phosphodiesterase type 3 ( PDE3 ) selectively increase amount cAMP inhibition degradation cyclic adenosine monophosphate ( cAMP ) . cAMP increase active form PKA suppress production blood clot increase blood flow expand blood vessel . Anti-platelet activity vasodilatation effect cilostazol use improvement diabetic peripheral vascular disorder suppression stroke recurrence . Previous study report increase activity NO PKA , blood flow stria vascularis cochlear hair cell improve . These study implies cilostazol , cause inhibition PDE3 increase PKA , potential effect improvement tinnitus increase blood flow peripheral cochlear cell . Thus , hypothesize cilostazol , widely use enhance peripheral blood flow , bring improvement tinnitus cause good peripheral blood flow cochlea . 3 . The aim study We plan study validate assumption background . The aim study whether administration cilostazol improve tinnitus term subjective degree symptom chronic tinnitus patient .</brief_summary>
	<brief_title>A Study Effect Cilostazol Patients With Chronic Tinnitus</brief_title>
	<detailed_description>1 . Clinical research method - Determination eligibility history taking , physical examination , pure tone audiometry , speech audiometry , distortion product otoacoustic emission test . - Randomization random sequence generation - Administration : cilostazol 100mg Bid 4 week study group placebo tablet Bid 4 week control group . - Evaluation battery : questionnaire ( tinnitus handicap inventory , visual analogue scale , Quality life SF-36 ) - Time evaluation : pre-administration , 2 week administration , 4 week administration - Monitoring side effect 2 . Evaluation treatment response - Statistical analysis score questionnaires use SPSS K12.0 ( pair t-test change group Mann-Whitney U test compare mean score two group )</detailed_description>
	<mesh_term>Tinnitus</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Adults age 19 Unilateral bilateral tinnitus Chronic tinnitus last 3 month Initial visual analogue scale tinnitus &gt; 3 Conductive hearing loss pure tone audiometry Associated inner ear diseases Meniere 's disease Objective pulsatile tinnitus Contraindication antiplatelet drug Any cardiac disease Bleeding tendency major operation within 3 month Breastfeeding Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Tinnitus</keyword>
	<keyword>Medication therapy management</keyword>
	<keyword>Cilostazol</keyword>
	<keyword>Antiplatelet agent</keyword>
</DOC>